Decreased aminotransferase activity of serum and various tissues in the rat after cefazolin treatment.
Treatment of rats with cefazolin in vivo significantly suppressed activity of alanine and aspartate aminotransferases in serum and in the liver, brain, kidney, and heart. Simultaneous administration of pyridoxal further reduced enzyme activity except in the liver, where there was no change. Pyridoxal 5'-phosphate partly reversed the decreased enzyme activity in the serum, liver, and kidney, but did not return it to the amount observed in the control animals; enzyme activity remained suppressed in the brain and heart. The effect of cefazolin was dose related, but there was no sex-related difference. In contrast to its action on am-notransferase activity, cefazolin elicited no effect on alkaline phosphatase (pyridoxal-5'-phosphate hydrolase) in serum or on pyruvate carboxylase in the liver, heart, and kidney. Cefazolin exposed to the hepatic microsomal mixed-function oxidase system in vitro was partly converted into metabolites that inhibited serum alanine aminotransferase activity in vitro. The latter inhibition was reversed by the addition of pyridoxal 5'-phosphate.
D000410:Alanine Transaminase / Q000097:blood / Q000378:metabolism; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood / Q000378:metabolism; D001921:Brain / Q000201:enzymology; D002437:Cefazolin / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D003864:Depression, Chemical; D005260:Female; D007668:Kidney / Q000201:enzymology; D008099:Liver / Q000201:enzymology; D008297:Male; D009206:Myocardium / Q000201:enzymology; D011732:Pyridoxal Phosphate / Q000494:pharmacology; D051381:Rats; D000637:Transaminases / Q000378:metabolism*
D002511:Cephalosporins; D011732:Pyridoxal Phosphate; D000637:Transaminases; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D002437:Cefazolin